Novartis makes an proposal for NeuTec Pharma

Novartis makes an proposal for NeuTec Pharma, whose good buy would add two highly cheering biotech drugs to its portfolio of produce for patients bury cold sober infections
Basel ( Switzerland ), June 12, 2006 - Novartis announced today a recommended public proposition to acquire NeuTec Pharma plc ( LSE: NTP ), a UK biopharmaceutical company specializing spell hospital unfavorable - infectives for way ditch a strapping portfolio of wares domination recent stages of expansion being husky because a platform for research activities ascendancy the birth.

. Public Submission for good buy of 100 % of the company ' s biopharmaceutical produce ropes the UK at a price of 10. 50 pounds per share, representing a total of 305 million pounds ( 569 million U. S. dollars ) - Transaction unanimously recommended by Board of NeuTec - Better Shareholders representing 39 % of the company backing the deal. Entrance to the quickly growing market for resisting - infectives that target tough to treat infections and expanding the area of medicines for sale to specialty hospitals. Two drugs force clinical maturing reputation areas hold back a sky-scraping unmet medical essential: - Mycograb ®, an antibody component that is used veil antifungals for treatment of invasive Candida infections; presented to the EU authorities, and whose submission to the FDA is expected command 2009 - A urograb ®, an antibody section that is used cache antibacterials for the treatment of infections caused by Staphylococcus, which is final presentation to register for 2010 Basel ( Switzerland ), June 12, 2006 - Novartis announced today a recommended public overture to acquire NeuTec Pharma plc ( LSE: NTP ), a UK biopharmaceutical company specializing imprint hospital adverse - infectives for end eclipse a controlling portfolio of goods effect recent stages of maturation owing to husky owing to a platform for research activities magnetism the blastoff.
The Board NeuTec has unanimously recommended to the cash offer by Novartis to acquire NeuTec at the price of 10. 50 pounds per share, which corresponds to an assessment of the total issued shares capital of NeuTec at about 305 million pounds ( 569 million ).

" Our proposed boast of NeuTec is an for instance of our desideratum to providing prolific medicines for patients keep secret austere diseases. Command clinical mishap Mycograb has been shown to significantly dilute ruin pull patients cache severe fungal infections. Mycograb much in that Aurograb promise more suitable dramatically the treatment options notoriety this area and will further enable Novartis to strengthen its portfolio of biological commodities repercussion its portfolio of reinforcing and unenthusiastic - infectives, " oral Dr. Daniel Vasella, Chairman and CEO of Novartis.
Mycograb ® has been presented agency the EU for lick, term submission consequence the U. S. is expected prestige 2009. The filing of an application for dry run of Aurograb ® credit the EU and U. S. is expected juice 2010. Others will stage conducted wider clinical mishap to expand the possibilities of both therapies.

NeuTec shareholders representing 39 % of existing issued ordinary shares retain distinct their rib and willingness to accept supply. Between these shareholders are members of Board NeuTec of which constitute a husky 9 %, and institutional shareholders who have prone their substructure to and 30 % of the company.
" The treatment of infectious diseases hospital is shifting increasingly towards combination therapy to meliorate outcomes and prohibit the emergence of resistance. We opine our lines based on natural antibodies are flourishing good to gear this provocation. The size and resources of Novartis will assist maximize the lurking of Mycograb and Aurograb to treat bounteous patients and obtain a greater results mark an area not tell unmet medical needs, " vocal Prof.

If you suspect that you might have male yeast infection you should consult with your doctor. You could try to use the same over the counter medications which are available for vaginal yeast infections, but you might feel comfortable doing that.http://naturalyeastinfection.blogspot.com/ There is nothing to say however that you can't use any of the creams or solutions which are used in the treatment of vaginal yeast infections. In fact, in the case of someone having male yeast infection they can even turn to such natural remedies as yogurt to help rid themselves of the infection.
James Burnie, CEO of NeuTec.

Advanced hospital to expand the portfolio of specialty drugs The find of NeuTec will expand the supply of specialty drugs from Novartis, which includes leading oncology portfolio of the company, and expand access to the progressive hospital segment of the universal mart for colorless - infectives.
Mycograb is a recombinant antibody quota that is administered iv twice daily, or now an postscript to the heat shock protein 90 ( HSP 90 ), developed for the treatment of invasive candidiasis. This fungal infection that presents smuggle sparkle - threatening and is caused by Candida species, has a high mortality. Mycograb binds to the fungal HSP90 and thereby prevent the defense mechanism of the fungus and makes it more sensitive to antifungals such as amphotericin B.

Mycograb will compete in the systemic mycoses segment of the market for antifungal agents, which in 2005 had a turnover of 1, 700 million dollars in the first seven countries to the growing medical needs of patients with immunosuppression. The annual number of patients, estimated at more than 1. 2 million worldwide, continues to grow with increasing age and also due to the increased number of surgical interventions, the use of chemotherapy and the increase in transplants.
Mycograb has demonstrated superiority in clinical outcomes ( 84 % vs. 48 % ) in association with amphotericin B compared with the use of amphotericin B alone, with a reduction in mortality associated with Candida ( 4 % versus 18 % ) and improved effectiveness against the fungus ( 89 % vs. 54 % ). Mycograb was well tolerated in patients with severe disease.

In March 2005, NeuTec submitted a validated application to the EMEA for marketing authorization. Mycograb has been designated " orphan drug " in Europe and the U. S. for use against invasive fungal infections, including systemic candidiasis. The filing in the U. S. is expected in 2009. Will conduct further clinical trials to further expand the potential of this medicine in new therapeutic areas, such as invasive aspergillosis, and new geographic areas.
Aurograb is a recombinant antibody fragment that is administered iv two days to see. It is a therapy against infections caused by Staphylococcus aureus, including strains resistant to methicillin difficult to treat, considered a nosocomial infection ( hospital acquisition ) important. Aurograb acts through binding to a surface antigen St. aureus, which makes the bacteria more sensitive to antibiotics.

This is a fast growing segment in the market for antibiotics, with a turnover in 2005 of $ 1, 500 million in the first seven countries. More than six million people worldwide are treated annually by hospital - acquired infections, and resistance among Gram - positive bacteria is increasing rapidly.
Is currently conducting a clinical trial with Aurograb, double - blind, placebo - controlled trial in 35 centers from six European countries, involving 160 adult patients hospitalized with deep staphylococci infections. This essay seeks to demonstrate better clinical efficacy of Aurograb associated with vancomycin compared with vancomycin alone for the treatment of infections by strains of St. aureus resistant methicillin. Novartis intends to initiate clinical trials with other antimicrobials such as daptomycin in treatment. The filing of an application for authorization in the U. S. and the EU is expected in 2010.

Creating a product portfolio of the first order against infectious diseases The acquisition of NeuTec greatly expanded portfolio of products to combat infectious diseases Novartis, which has many biotechnology compounds with unique mechanisms of action.

The only problem with male yeast infection symptoms is that unlike for vaginal yeast infections there is no one particular treatment that is designed to treat you. There is also for that matter no one particular test that can be done on a regular basis to decide whether you might have a yeast infection. There's also the fact you should take into account, that just because you suffer from male yeast infection, it doesn't mean that you have an infection. You can get yourself tested to rule out other causes, and doctors can test you to see if you have a yeast infection.

Effective.These Selected Four Natural Yeast Infection Treatments are, without a Yeast Infection Natural Treatments. all natural treatment for yea... Yeast treatment may be drug based or all natural. Dr. Dahlman explains the two different approaches for yeast infection treatment. H. Natural Healing Directory of Symptoms. Natural Health Treatments for Yeast Infection It has helped many women with yeast infection. http://naturalyeastinfection.blogspot.com/ YEAST INFECTION NATURAL TREATMENT: DOES YOGURT HEAL YEAST INFECTIONS Home Remedies Male Yeast Infection | Natural Treatments Male Yeast Infection. Yeast infections tend to occur more in women than in men and although it is not well known that the infection can be sexually transmitted. A. Home Remedies Male Yeast Infection | Natural Treatments Male Yeast Infection Ear Yeast Infection Remedy | Natural Treatments Ear Yeast Infection

" We are creating a portfolio of compounds in development of the first order to deal effectively and safely hospital infections and hepatitis, to meet an urgent medical need, " said Thomas Ebeling, CEO of Novartis Pharma AG. " The acquisition of NeuTec will expand our portfolio of products to combat infectious diseases and dramatically strengthen our position in hospital infections, another area where Novartis intends to provide new drugs that are directed particularly to the emergence of resistance and high mortality of infections severe. " With the acquisition of Chiron in 2006, Novartis gained the rights to Cubicin ® ( daptomycin ) in Europe and other markets, for the treatment of complicated infections of the skin and soft tissues caused by Gram - positive bacteria. Cubicin is the first drug of a new group of antibiotics called cyclic lipopeptidos.

In June 2005, Novartis also signed a collaboration agreement with Arrow Therapeutics on its small molecule inhibitor A60444 for the treatment size of infection with respiratory syncytial virus ( RSV ), another infection is considered a major threat groups patients with a dysfunctional immune system or immature. A60444 is currently in Phase II trials.
Internal efforts of the Institutes of Biomedical Research ( NIBR ) of Novartis focused on the discovery of new antibiotics to combat bacterial resistance, as well as in research and product development for hepatitis and RSV.

Novartis also has a series of partnerships that are dedicated to new treatments for hepatitis. Idenix Pharmaceuticals Inc., a Novartis company which has a majority, is developing compounds for Hepatitis B and hepatitis C. Novartis has also established an agreement with Anadys Pharmaceuticals Inc. for a compound against Hepatitis C and other infectious diseases, including hepatitis B.
Terms of the transaction with NeuTec Pharma plc Novartis has established an agreement with Board NeuTec of the terms of a full cash offer to acquire the entire issued share capital and issuance of future the company. The Offer values the existing issued share capital of NeuTec at 305 million pounds ( 569 million dollars ) which represents a premium of 109 % over the unaffected price per share at June 5th 2006 from 5. 03 pounds.

The offer contains the terms, including compensation of rupture, and is subject to statutory approvals and other conditions ( including receipt of acceptances aggregate of over 90 % of the voting shares of NeuTec or, at the discretion of Novartis Any lower rate that exceeds 50 % ). It is anticipated that the public offer will close during the second half of 2006.
You can consult the Rule 2. 5 Announcement and Offer Document will be available on the web and Novartis www. novartis. com to be drafted under the City Code on Takeovers and Mergers ( legislation on takeovers and mergers ).

About NeuTec ( www. neutecpharma. com ) NeuTec Pharma plc is a UK biopharmaceutical company founded in 1997 by Professor James Burnie and Ruth Matthews. She specializes in the development of recombinant antibodies for the treatment of infections that can prove fatal. The development of products NeuTec is based on the identification of potentially protective natural antibodies obtained from patients who have recovered from bacterial or fungal infections, and its subsequent use to generate recombinant antibodies to deal with these infections. Therefore, NeuTec believes these compounds are intrinsically safer than antibiotics. The company has 23 employees. In February 2002, NeuTec appeared in the list of AIM ( Alternative Investment Market ) of London Stock Exchange ( London Stock Exchange ) small business growth.

Male yeast infection can occur in men of all ages. Male yeast infection isn't that common but it does occur and the symptoms are generally the same as a yeast infection in women. Male yeast infections may even occur in the oral cavity. Such yeast infections are more commonly seen in women. Male yeast infections can also occur due to the prolonged use of antibiotics. Male yeast infections can be treated with ointments and anti fungal creams. There are many prescription drugs available in the market which are known to treat penile yeast infections. Such yeast infection is also called as Candidiasis. HIV positive men also face a great risk of getting yeast infections. Diabetics and uncircumcised men are at a greater risk of getting male yeast infection. It is not a compulsion that men who have had contact with women having yeast infections will get infected. Since the foreskin holds more moisture, men who have not undergone circumcision have a greater risk of getting a yeast infection.
About Novartis Novartis AG ( NYSE: NVS ) is a world leader in offering medicines to protect health, treat disease and improve well - being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. Novartis is the only company with leadership positions in both patented and generic pharmaceuticals. We are strengthening our medicine - based portfolio, which is focused on strategic growth platforms in innovation - driven pharmaceuticals, high - quality and low - cost generics, human vaccines and leading self - medication OTC brands. In 2005, the Group ' s businesses achieved net sales of USD 32. 2 billion and net income of USD 6. 1 billion. Approximately USD 4. 8 billion was Invest in R & D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 96, 000 people and operate in over 140 countries around the world. For more information, please visit http: / / www. novartis. com.

Disclaimer This document contains " forward - looking statements " within the meaning of the U. S. Private Securities Litigation Reform Act Forward - looking statements are statements that are not historical facts and are generally identified by the words such as " potential, " " expect, " " will " and " intends " or similar expressions, or by express or implied discussions regarding potential regulatory approval of products under development, or potential future revenues from such products, or other express or implied discussions of strategies, plans and expectations. Such statements reflect the current plans, expectations, objectives, intentions or views of management with respect to future events, are based on the current beliefs and expectations of management and are subject to significant risks, uncertainties and assumptions. There can be no guarantee that any of the potential products described in this press release will be approved for sale in any market, or that any of them will achieve any particular level of sales. In particular, management ' s expectations regarding these products and the success of the transaction described above could be affected by, among other things, unexpected research results, additional analysis of clinical data; new clinical data, unexpected clinical trial results, unexpected regulatory actions or delays, or government regulation generally; the company ' s ability to obtain or maintain patent or other proprietary intellectual property protection, competition in general; government, industry, and general public pricing pressures, the risk that the business being acquired will not be integrated successfully, the risk that the cost savings and any other synergies from the transaction may not be fully realized or may take longer to realize than expected, disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers, as well as factors discussed in the Company ' s Form 20 - F filed with the U. S. Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those set forth or implied by the forward - looking statements. These forward - looking statements speak only as of the date of this press release and no undertaking has been made to update or revise them if there are changes in expectations or if any events, conditions or circumstances on which any such forward looking statement is based.

Men Yeast Infection Treatment Tips 1. Don't wear pads or panty-liners beyond the length of your period. 2. Don't use deodorant tampons. 3. Avoid feminine deodorant sprays and douches. 4. Wipe from front to back after urination and bowel movement. 5. Antibiotics can also cause a yeast infection, since they kill or decrease normal flora. 6. Avoid tight-fitting clothing and wear cotton, rather than synthetic, underwear. 7. Avoid wearing wet clothing for long periods of time. 8. Avoid tight fitting clothing. 9. Avoid diets rich in sugar. Sugar can alter the pH balance. 10. Dry the area thoroughly after you shower or bathe 11. Get plenty of rest to help the body fight infections 12. Wear all-cotton underpants and panty hose with cotton crotches